CRBU
Caribou Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.57
+0.00%Aug 13, 2026, 23:06 UTC
Caribou Biosciences, Inc. reported a Q2 2026 net loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.33 loss and improved from a $0.35 loss a year earlier.
Source:Aug 13, 2026, 00:00 UTC
Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.
Jun 11, 2026, 12:00 UTC
Caribou Biosciences presented phase 1 clinical data for its CAR-T cell therapy candidate vispacabtagene regedleucel (vispa-cel) at the 2026 European Hematology Association Annual Meeting, showing a median progression-free survival of 17.1 months in second-line large B cell lymphoma patients.
Source: